A Matter of Supply and Demand
Research - Ionis (IONS) gained about $1.2 billion in market value this week when a phase 3 study of nusinersen, the company’s antisense drug for Spinal Muscular … Continue Reading
PremiumMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
What UniQure Needs for a Sea Change
Research - We’ve been discussing the potential for biotech to play some catchup to the broader market in our monthly webinars of late, and the move is … Continue Reading
Premium
It May Not Be Too Late To Participate in a Medivation Deal
Research - A last-minute trade idea for this slow Friday afternoon. As most healthcare investors will be aware, Sanofi (SNY) has made public their desire to purchase … Continue Reading
Premium
Catch July’s ‘Healthcare Huddle’ Webinar
Research - On Thursday evening we hosted our monthly ‘Healthcare Huddle’ webinar. We discussed: The state of the markets (why we’re cautiously bullish about equities) The state … Continue Reading
Premium
For The Trial, Sage’s Depression Results Couldn’t Be Better
Research - Sage Therapeutics’s (SAGE) Postpartum Depression results are stellar. Even with a smaller sample size (21 patients as opposed to an enrollment goal of 32), SAGE-547 … Continue Reading
Premium
One Reason to Be Optimistic
Insights - After a tumultuous and breathtaking plunge earlier this week, equities have rebounded in a big way. That’s quite constructive. The UK’s vote to leave the EU … Continue Reading
Premium
Market Participants Love Strawman Issues
Insights - Market Participant Love Strawman Issues
Read now